NSP 808

Drug Profile

NSP 808

Latest Information Update: 18 Sep 2006

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals; Wyeth
  • Class Hormonal replacements; Oral contraceptives
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Menopausal syndrome; Pregnancy

Most Recent Events

  • 18 Sep 2006 Discontinued - Preclinical for Menopausal syndrome in USA (unspecified route)
  • 18 Sep 2006 Discontinued - Preclinical for Pregnancy (Prevention) in USA (unspecified route)
  • 05 Mar 2003 Preclinical trials in Menopausal syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top